Supplemental Table 1: All adverse events and adverse events with possible, probable, or definitive attribution to everolimus and/ or bevacizumab (highest grade-CTCAEv4- per patient) that occurred in more than 1 patient (4%). Total number of 25 patients (percent).

Adverse events		All adverse events								
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Blood and lymphatic system disorders										
Anemia			1 (4)				1 (4)	2 (8)		
Platelet count decreased	3 (12)	1 (4)				3 (12)	1 (4)			
White blood cell decreased	2 (8)					2 (8)		1 (4)		
Gastrointestinal disorders										
Constipation	1 (4)	1 (4)				4 (16)	1 (4)			
Diarrhea	2 (8)					3 (12)		1 (4)		
Dyspepsia	1 (4)	1 (4)				1 (4)	1 (4)			
Mucositis oral	6 (24)	2 (8)	5 (20)			6 (24)	2 (8)	5 (20)		
Oral pain		1 (4)	1 (4)				1 (4)	1 (4)		
Nausea	4 (16)	3 (12)				5 (20)	3 (12)			
Vomiting	2 (8)	2 (8)	1 (4)			3 (12)	2 (8)	1 (4)		
General disorders										

Adverse events		Relate	All adverse events							
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Fever	1 (4)					2 (8)				
Fatigue	5 (20)	3 (12)	2 (8)			5 (20)	4 (16)	2 (8)		
Investigations										
Alanine aminotransferase increased		1 (4)	2 (8)				1 (4)	2 (8)		
Creatinine increased	2 (8)					2 (8)	1 (4)			
Weight loss	5 (20)	1 (4)	1 (4)			5 (20)	2 (8)	1 (4)		
Metabolism and nutrition										
Anorexia	2 (8)	4 (16)	1 (4)			2 (8)	4 (16)	1 (4)		
Cholesterol high	2 (8)	1 (4)				3 (12)	1 (4)			
Dehydration	1 (4)	1 (4)	1 (4)			1 (4)	2 (8)	1 (4)		
Hypertriglyceridemia	1 (4)	1 (4)		1 (4)		1 (4)	1 (4)		1 (4)	
Hypokalemia	1 (4)					1 (4)		2 (8)		
Hyponatremia			1 (4)					2 (8)		
Hypophosphatemia		1 (4)	3 (12)				1 (4)	4 (16)		
Nervous system disorder										

Adverse events		Relate	All adverse events							
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Headache	1 (4)	1 (4)				2 (8)	1 (4)			
Pain										
Pain (neck, back, chest wall, ear, flank)	3 (12)	1 (4)				6 (24)	4 (16)	1 (4)		
Renal and urinary disorders										
Proteinuria	1 (4)	3 (12)				1 (4)	3 (12)			
Respiratory, thoracic, and mediastinal										
disorders										
Epistaxis	3 (12)					3 (12)				
Nasal congestion	1 (4)		1 (4)			1 (4)		1 (4)		
Dyspnea	1 (4)	2 (8)				2 (8)	2 (8)			
Sore throat		2 (8)	1 (4)				2 (8)	1 (4)		
Skin and subcutaneous tissue										
disorders										
Dry skin	1 (4)					2 (8)				
Vascular disorders										

SARC016 Manuscript: Supplementary Data Table

Adverse events		All adverse events								
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Hypertension	3 (12)	2 (8)	1 (4)			3 (12)	2 (8)	1 (4)		